In 2018, Japanese multinational conglomerate Fujifilm up and decided it wanted to become a major player in supplying cell and gene therapy manufacturing, so it purchased two key companies—one in the U.S. and in the other in Japan—to jump-start its goal.
Four years later, the spending spree continues: Fujifilm has gobbled up Shenandoah Biotechnology for an undisclosed sum, again to increase its cell and gene therapy capabilities.
The Warminster, Pennsylvania-based Shenandoah boosts Fujifilm’s ability to produce recombinant proteins—especially growth factors and cytokines—used in manufacturing cell and gene therapies.
Shenandoah also comes with an upgraded cGMP facility with bio-command software, a new Tuttnauer autoclave sterilizer, a 16×16 ColdBox, and new air handling and RODI water systems, according to its website.
“Shenandoah Biotechnology’s portfolio of recombinant proteins complement our advanced cell culture solutions and expertise in bioprocessing, providing our collective customers a single point of access for their life science research, discovery, and cell and gene therapy needs,” Yutaka Yamaguchi, CEO of Fujifilm Irvine Scientific, said in a release.
Fujifilm said it welcomed “all members” of the Shenandoah team. The privately held company was established in 2006.
In 2018, Fujifilm dove headfirst into the cell and gene therapy supply business with its simultaneous acquisition of Irvine Scientific Sales of California and IS Japan for $800 million.
Then, in September of last year, Fujifilm completed construction of a 250,000-square-foot facility in Tilburg, Netherlands. The site produces dry powder media and liquid media along with other raw materials used in producing cell and gene therapies. It also gave Fujifilm Irvine Scientific a hub from which to serve its customers in Europe.
By Kevin Dunleavy
A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.
Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.
Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”